Ertugliflozin in Acute Heart Failure
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Ertugliflozin in Acute Heart Failure is a clinical trial[1].
Key Facts
- Ertugliflozin in Acute Heart Failure is in the country of United States[2].
- Ertugliflozin in Acute Heart Failure's instance of is recorded as clinical trial[3].
- Ertugliflozin in Acute Heart Failure's start time is recorded as +2020-07-31T00:00:00Z[4].
- Ertugliflozin in Acute Heart Failure's end time is recorded as +2022-01-31T00:00:00Z[5].
- Ertugliflozin in Acute Heart Failure's contributor to the creative work or subject is recorded as Merck Sharp & Dohme[6].
- Ertugliflozin in Acute Heart Failure's main subject is recorded as metolazone[7].
- Ertugliflozin in Acute Heart Failure's main subject is recorded as heart failure[8].
- Ertugliflozin in Acute Heart Failure's number of participants is recorded as {'unit': '1', 'amount': '+90'}[9].
- Ertugliflozin in Acute Heart Failure's title is recorded as Ertugliflozin in Acute Heart Failure: Cardio-renal and Diuretic Effects[10].
- Ertugliflozin in Acute Heart Failure's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
- Ertugliflozin in Acute Heart Failure's ClinicalTrials.gov ID is recorded as NCT04438213[12].
- Ertugliflozin in Acute Heart Failure's research intervention is recorded as adenosine triphosphate[13].
- Ertugliflozin in Acute Heart Failure's research intervention is recorded as metolazone[14].
- Ertugliflozin in Acute Heart Failure's clinical trial phase is recorded as phase II clinical trial[15].
- Ertugliflozin in Acute Heart Failure's research site is recorded as Yale University[16].
- Ertugliflozin in Acute Heart Failure's research subject recruitment status is recorded as not yet recruiting[17].
- Ertugliflozin in Acute Heart Failure's study type is recorded as interventional study[18].